BioImagene, a Cupertino, CA based company with its development centre in India, is a leading provider of innovative digital pathology solutions for research and cancer diagnosis and innovative systems that support automation of an integrated pathology work flow. BioImagene seeks to accelerate the adoption of digital pathology through its disruptive and capital efficient business model that has helped lower the cost of entry into digital pathology both in the research and the clinical diagnostics market. It was the first company to obtain FDA clearance for a specific image analysis algorithm for HER2/neu that aids the pathologist in determining the efficacy of Herceptin as a treatment for breast cancer.


Website: http://www.bioimagene.com/